m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03298)
Name
SB-265123
Synonyms
SB-265123; CHEMBL288493; SCHEMBL244383; HODBWQCCKYDYPY-NRFANRHFSA-N; {3-[3-(Pyridin-2-ylamino)-propoxy]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl}-acetic acid; BDBM50078714; {(S)-3-[3-(Pyridin-2-ylamino)-propoxy]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl}-acetic acid; (S)-10,11-Dihydro-3-[3-(pyridin-2-ylamino)-1-propyloxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid
    Click to Show/Hide
Status
Investigative
Structure
Formula
C25H26N2O3
InChI
1S/C25H26N2O3/c28-25(29)17-21-14-18-9-10-22(16-20(18)15-19-6-1-2-7-23(19)21)30-13-5-12-27-24-8-3-4-11-26-24/h1-4,6-11,16,21H,5,12-15,17H2,(H,26,27)(H,28,29)/t21-/m0/s1
InChIKey
HODBWQCCKYDYPY-NRFANRHFSA-N
PubChem CID
9952958
TTD Drug ID
D0R3CY
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Integrin beta-1 (ITGB1)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Integrin beta-1 (ITGB1) is a therapeutic target for SB-265123. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of SB-265123 through regulating the expression of Integrin beta-1 (ITGB1). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Integrin beta-1 (ITGB1) is a therapeutic target for SB-265123. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SB-265123 through regulating the expression of Integrin beta-1 (ITGB1). [2], [3]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Integrin beta-1 (ITGB1) is a therapeutic target for SB-265123. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of SB-265123 through regulating the expression of Integrin beta-1 (ITGB1). [2], [4]
ITGB3 messenger RNA (ITGB3 mRNA)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for SB-265123. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SB-265123 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). [5], [6]
References
Ref 1 N(6)-Methyladenosine RNA Demethylase FTO Promotes Gastric Cancer Metastasis by Down-Regulating the m6A Methylation of ITGB1. Front Oncol. 2021 Jul 1;11:681280. doi: 10.3389/fonc.2021.681280. eCollection 2021.
Ref 2 Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem. 2007 Nov 29;50(24):5878-81. doi: 10.1021/jm701044r. Epub 2007 Nov 1.
Ref 3 METTL3 enhances cell adhesion through stabilizing integrin Beta1 mRNA via an m6A-HuR-dependent mechanism in prostatic carcinoma. Am J Cancer Res. 2020 Mar 1;10(3):1012-1025. eCollection 2020.
Ref 4 KAT1 triggers YTHDF2-mediated ITGB1 mRNA instability to alleviate the progression of diabetic retinopathy. Pharmacol Res. 2021 Aug;170:105713. doi: 10.1016/j.phrs.2021.105713. Epub 2021 Jun 5.
Ref 5 Long Noncoding RNA FAM225A Promotes Nasopharyngeal Carcinoma Tumorigenesis and Metastasis by Acting as ceRNA to Sponge miR-590-3p/miR-1275 and Upregulate ITGB3. Cancer Res. 2019 Sep 15;79(18):4612-4626. doi: 10.1158/0008-5472.CAN-19-0799. Epub 2019 Jul 22.
Ref 6 Preparation and Properties of a fibrinogen receptor antagonist containing the Arg-Gly-Asp sequence and nitroxide radicals, Bioorg. Med. Chem. Lett. 3(6):1179-1184 (1993).